FDA approval of obesity drugs: a difference in risk-benefit perceptions

JAMA. 2012 Sep 19;308(11):1097-8. doi: 10.1001/jama.2012.10007.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Anti-Obesity Agents / adverse effects*
  • Anti-Obesity Agents / therapeutic use
  • Decision Making
  • Drug Approval*
  • Humans
  • Obesity / drug therapy*
  • Perception
  • Risk*
  • United States
  • United States Food and Drug Administration

Substances

  • Anti-Obesity Agents